Condition
Alcohol-related Liver Disease
Locations
Australia, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece,
Japan, Netherlands, Poland, Spain, United States
Start date
20/05/2024
Identifiers
Trial ID
NN9500-7730,
NCT number NCT06409130,
Eudract number Not Available
NCT number NCT06409130,
Eudract number Not Available
Summary
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Trial Overview:
Treatment
DRUG: NNC0194-0499
DRUG: Semaglutide
DRUG: NNC0194-0499 placebo
DRUG: Semaglutide placebo (Group A)
DRUG: Cagrilintide + semaglutide
DRUG: Cagrilintide
DRUG: Cagrilintide placebo
DRUG: Semaglutide placebo (Group B)
Study type
INTERVENTIONAL
Trial duration
May 20 2024 - Jan 16 2026
Participants
240
Phase
II
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.